| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Traws Pharma Inc Com par $0.01 (New) | Rigosertib | Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma | Phase 2 | Trial Completed | Oral or intravenous | Oncology |
| Traws Pharma Inc. | Rigosertib plus the PD-1 inhibitor pembrolizumab (Oral) | Melanoma | Phase 2 | Ongoing | Oral | Oncology |
| Traws Pharma Inc. | Ratutrelvir | COVID-19 | Phase 2 | Data Released | Oral | COVID-19 |
| Traws Pharma Inc. | Tivoxavir Marboxil | H5N1 avian influenza | Phase 2 | Trial Planned | Oral | Antiviral |
| Traws Pharma Inc. | Rigosertib | Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma | Phase 2 | Trial Completed | Oral or intravenous | Oncology |
| Trevena Inc. | TRV027 | COVID-19 | Phase 2/3 | Trial Discontinued | Intravenous | COVID-19 |
| Trevena Inc. | TRV734 | Opioid use disorder | Phase 2 | Trial Discontinued | oral | Anti-Addiction |
| Trevena Inc. | TRV027 - BLAST-AHF | Acute heart failure | Phase 2a | Trial Discontinued | Intravenous | Cardiology |